Literature DB >> 9399211

Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease.

J N Joyce1, G Smutzer, C J Whitty, A Myers, M J Bannon.   

Abstract

The molecular characteristics of midbrain dopamine (DA) neurons have been extensively studied in Parkinson's disease (PD). No such studies of the characteristics of midbrain DA neurons in Alzheimer's disease (AD) or Alzheimer's disease with parkinsonism (AD/Park) have been published. We examined the levels of tyrosine hydroxylase (TH) protein, and the expression of TH and dopamine transporter (DAT) mRNAs, in midbrain neurons of PD, AD, and AD/Park cases. In PD, the loss of TH protein in the ventral tier of the substantia nigra pars compacta (SNpc) of the PD group in accompanied by severe losses in the number of neurons that express TH mRNA and DAT mRNA (74% loss). Remaining neurons show a shift to higher concentrations of TH mRNA but a shift to lower concentrations of DAT mRNA per cell. Hence, there is evidence that compensation in the remaining neurons can elevate concentrations of TH mRNA and lower DAT mRNA. Alternatively, there may be a predilection for a loss of neurons with high levels of DAT mRNA and low TH mRNA levels within the SNpc of PD cases. There was no change in TH protein but an elevation of TH mRNA concentrations per neuron without any change in concentrations of DAT mRNA in the AD group. The AD/Park group did not exhibit changes in the level of TH protein, but showed a small loss (26%) of neurons in the SNpc and a greater loss in other regions of the midbrain (43-53%). Remaining DA neurons showed a marked shift to lower concentrations of DAT mRNA per neuron and a nonsignificant shift in cellular concentration of TH mRNA to higher levels. This is consistent with our previous work showing that with AD/Park there is a significant reduction in the number of DAT sites located on DA terminals in the striatum, but the midbrain neurons have not died. Our results indicate that the differential regulation of mRNAs encoding TH and DAT is similar in the parkinsonian disorders (PD and AD/Park) even though the degree of cell death is very different. This might suggest that compensatory events occur in these DA neurons in AD/Park that are similar to those in PD and that result in differential effects on mRNAs encoding TH and DAT proteins.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9399211     DOI: 10.1002/mds.870120609

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  19 in total

1.  Delayed increase of tyrosine hydroxylase expression in rat nigrostriatal system after traumatic brain injury.

Authors:  Hong Qu Yan; Xiecheng Ma; Xiangbai Chen; Youming Li; Lifang Shao; C Edward Dixon
Journal:  Brain Res       Date:  2006-12-28       Impact factor: 3.252

2.  Expression of striatal preprotachykinin mRNA in symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys is related to parkinsonian motor signs.

Authors:  T V Wade; J S Schneider
Journal:  J Neurosci       Date:  2001-07-01       Impact factor: 6.167

3.  Distinct FP-CIT PET patterns of Alzheimer's disease with parkinsonism and dementia with Lewy bodies.

Authors:  Seok Jong Chung; Yang Hyun Lee; Han Soo Yoo; Young H Sohn; Byoung Seok Ye; Jungho Cha; Phil Hyu Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-04-12       Impact factor: 9.236

4.  Ventral midbrain correlation between genetic variation and expression of the dopamine transporter gene in cocaine-abusing versus non-abusing subjects.

Authors:  Yanhong Zhou; Sharon K Michelhaugh; Carl J Schmidt; Jun S Liu; Michael J Bannon; Zhicheng Lin
Journal:  Addict Biol       Date:  2011-10-26       Impact factor: 4.280

Review 5.  Human genetics of plasma dopamine beta-hydroxylase activity: applications to research in psychiatry and neurology.

Authors:  J F Cubells; C P Zabetian
Journal:  Psychopharmacology (Berl)       Date:  2004-04-16       Impact factor: 4.530

Review 6.  Parkinson's disease: is the initial treatment established?

Authors:  J Eric Ahlskog
Journal:  Curr Neurol Neurosci Rep       Date:  2003-07       Impact factor: 5.081

7.  Id2 is required for specification of dopaminergic neurons during adult olfactory neurogenesis.

Authors:  Matthew C Havrda; Brent T Harris; Akio Mantani; Nora M Ward; Brenton R Paolella; Verginia C Cuzon; Hermes H Yeh; Mark A Israel
Journal:  J Neurosci       Date:  2008-12-24       Impact factor: 6.167

8.  Abnormal striatal dopaminergic synapses in National NeuroAIDS Tissue Consortium subjects with HIV encephalitis.

Authors:  Benjamin B Gelman; Jeffrey A Spencer; Charles E Holzer; Vicki M Soukup
Journal:  J Neuroimmune Pharmacol       Date:  2006-08-08       Impact factor: 4.147

9.  Catechol-O-methyltransferase genotype and dopamine regulation in the human brain.

Authors:  Mayada Akil; Bhaskar S Kolachana; Debora A Rothmond; Thomas M Hyde; Daniel R Weinberger; Joel E Kleinman
Journal:  J Neurosci       Date:  2003-03-15       Impact factor: 6.167

10.  Dopamine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson's disease from essential tremor.

Authors:  C Pellicano; F R Buttarelli; A Circella; D Tiple; M Giovannelli; D Benincasa; C Colosimo; F E Pontieri
Journal:  J Neural Transm (Vienna)       Date:  2007-01-29       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.